+検索条件
-Structure paper
タイトル | Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. |
---|---|
ジャーナル・号・ページ | NPJ Vaccines, Vol. 6, Issue 1, Page 5, Year 2021 |
掲載日 | 2021年1月8日 |
著者 | Mohammad W Bahar / Claudine Porta / Helen Fox / Andrew J Macadam / Elizabeth E Fry / David I Stuart / |
PubMed 要旨 | Global vaccination programs using live-attenuated oral and inactivated polio vaccine (OPV and IPV) have almost eradicated poliovirus (PV) but these vaccines or their production pose significant risk ...Global vaccination programs using live-attenuated oral and inactivated polio vaccine (OPV and IPV) have almost eradicated poliovirus (PV) but these vaccines or their production pose significant risk in a polio-free world. Recombinant PV virus-like particles (VLPs), lacking the viral genome, represent safe next-generation vaccines, however their production requires optimisation. Here we present an efficient mammalian expression strategy producing good yields of wild-type PV VLPs for all three serotypes and a thermostabilised variant for PV3. Whilst the wild-type VLPs were predominantly in the non-native C-antigenic form, the thermostabilised PV3 VLPs adopted the native D-antigenic conformation eliciting neutralising antibody titres equivalent to the current IPV and were indistinguishable from natural empty particles by cryo-electron microscopy with a similar stabilising lipidic pocket-factor in the VP1 β-barrel. This factor may not be available in alternative expression systems, which may require synthetic pocket-binding factors. VLPs equivalent to these mammalian expressed thermostabilized particles, represent safer non-infectious vaccine candidates for the post-eradication era. |
リンク | NPJ Vaccines / PubMed:33420068 / PubMed Central |
手法 | EM (単粒子) |
解像度 | 3.0 Å |
構造データ | EMDB-11106, PDB-6z6w: |
化合物 | ChemComp-SPH: |
由来 |
|
キーワード | VIRUS LIKE PARTICLE / Capsid protein |